Credit Suisse’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$141M Sell
2,058,101
-62,865
-3% -$4.04M 0.13% 142
2023
Q4
$123M Buy
2,120,966
+129,116
+6% +$6.89M 0.12% 162
2023
Q3
$105M Buy
1,991,850
+2,213
+0.1% +$116K 0.11% 184
2023
Q2
$108M Sell
1,989,637
-69,854
-3% -$3.65M 0.11% 186
2023
Q1
$103M Sell
2,059,491
-18,457
-0.9% -$870K 0.1% 195
2022
Q4
$96.1M Sell
2,077,948
-11,841
-0.6% -$513K 0.1% 206
2022
Q3
$80.9M Sell
2,089,789
-54,317
-3% -$2.18M 0.09% 231
2022
Q2
$79.9M Sell
2,144,106
-18,250
-0.8% -$743K 0.08% 248
2022
Q1
$95.8M Buy
2,162,356
+60,757
+3% +$2.63M 0.08% 265
2021
Q4
$89.3M Buy
2,101,599
+159,323
+8% +$6.69M 0.05% 407
2021
Q3
$84.3M Buy
1,942,276
+88,002
+5% +$3.89M 0.05% 427
2021
Q2
$80.2M Sell
1,854,274
-459,523
-20% -$19.3M 0.04% 466
2021
Q1
$89.4M Sell
2,313,797
-158,817
-6% -$6.01M 0.05% 446
2020
Q4
$88.9M Buy
2,472,614
+334,879
+16% +$12.1M 0.04% 463
2020
Q3
$81.7M Sell
2,137,735
-191,269
-8% -$7.37M 0.05% 414
2020
Q2
$81.8M Buy
2,329,004
+19,217
+0.8% +$692K 0.06% 344
2020
Q1
$75.4M Sell
2,309,787
-93,760
-4% -$3.66M 0.07% 292
2019
Q4
$109M Buy
2,403,547
+405,175
+20% +$17M 0.08% 251
2019
Q3
$81.3M Buy
1,998,372
+34,346
+2% +$1.46M 0.07% 288
2019
Q2
$84.4M Buy
1,964,026
+385,820
+24% +$14.8M 0.07% 263
2019
Q1
$60.6M Sell
1,578,206
-180,176
-10% -$6.88M 0.06% 348
2018
Q4
$62.1M Sell
1,758,382
-60,298
-3% -$2.19M 0.06% 308
2018
Q3
$70M Buy
1,818,680
+72,865
+4% +$2.54M 0.06% 312
2018
Q2
$57.1M Sell
1,745,815
-55,742
-3% -$1.68M 0.06% 349
2018
Q1
$49.2M Sell
1,801,557
-435,527
-19% -$11.8M 0.05% 421
2017
Q4
$55.5M Buy
2,237,084
+225,507
+11% +$6.22M 0.05% 391
2017
Q3
$58.7M Buy
2,011,577
+44,538
+2% +$1.23M 0.06% 369
2017
Q2
$58.5M Sell
1,967,039
-201,192
-9% -$5.34M 0.06% 346
2017
Q1
$53.9M Buy
2,168,231
+23,686
+1% +$576K 0.05% 407
2016
Q4
$46.4M Sell
2,144,545
-95,290
-4% -$2.08M 0.05% 441
2016
Q3
$53.3M Buy
2,239,835
+278,518
+14% +$6.64M 0.05% 399
2016
Q2
$45.8M Sell
1,961,317
-593,200
-23% -$12.8M 0.05% 409
2016
Q1
$48.1M Buy
2,554,517
+929,980
+57% +$16.3M 0.06% 358
2015
Q4
$30M Buy
1,624,537
+160,593
+11% +$2.88M 0.03% 587
2015
Q3
$24M Sell
1,463,944
-309,789
-17% -$5.3M 0.03% 644
2015
Q2
$31.4M Buy
1,773,733
+48,384
+3% +$865K 0.03% 602
2015
Q1
$30.6M Sell
1,725,349
-613,990
-26% -$9.7M 0.03% 627
2014
Q4
$31M Sell
2,339,339
-82,059
-3% -$1.05M 0.03% 671
2014
Q3
$28.6M Sell
2,421,398
-355,135
-13% -$4.47M 0.02% 755
2014
Q2
$35.5M Buy
2,776,533
+548,185
+25% +$7.13M 0.03% 649
2014
Q1
$30.1M Sell
2,228,348
-462,330
-17% -$6.07M 0.03% 638
2013
Q4
$32.3M Sell
2,690,678
-40,135
-1% -$474K 0.03% 585
2013
Q3
$32.1M Sell
2,730,813
-1,279,347
-32% -$13.8M 0.03% 510
2013
Q2
$37.2M Buy
+4,010,160
New +$34M 0.04% 478

Other funds holding BSX

Credit Suisse's BSX Position: Q1 2024 in Review

Credit Suisse reduced its Boston Scientific (BSX) stake by 3% in Q1 2024, selling an estimated $4.04M and leaving 2,058,101 shares worth $141M. The position accounts for 0.13% of the portfolio, ranked #142.

Credit Suisse first reported a position in BSX in Q2 2013 and has held it in 44 quarters since. 1,222 funds tracked by Wall St. Rank hold BSX as of Q1 2024.

  • Credit Suisse held 2,058,101 shares of Boston Scientific worth $141M as of Q1 2024.
  • Credit Suisse sold 62,865 Boston Scientific shares in Q1 2024, an estimated $4.04M.
  • Boston Scientific made up 0.13% of Credit Suisse's portfolio in Q1 2024, its #142 holding.
  • Credit Suisse first reported a position in Boston Scientific in Q2 2013 and has held it in 44 quarters since.
  • 1,222 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.